GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv (UCHT1) for phase I/II clinical trials

JH Woo, JS Liu, SH Kang, R Singh, SK Park… - Protein expression and …, 2008 - Elsevier
The bivalent anti-T cell immunotoxin, A-dmDT390-bisFv (UCHT1), was developed for
treatment of T-cell leukemia, autoimmune diseases and tolerance induction for
transplantation. To obtain clinical grade bivalent anti-T cell immunotoxin for phase I/II clinical
trials, a single batch of 120L bioreactor culture was performed using the Pichia pastoris
mutEF2JC307-8 (2) strain expressing the bivalent anti-T cell immunotoxin. After 162h
induction of the culture by methanol, the culture medium was harvested by a 0.1 μm hollow …